
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
2
Myopia-related retinal detachments in younger patients: A retina view
3
Real-world study of enVista Aspire IOL reports over 90% patient satisfaction
4
Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunction
5













